title: Radiation and chemoradiation therapy for esophageal adenocarcinoma.
abstract: The aims of preoperative chemoradiation therapy (preop-CRT) for esophageal adenocarcinoma are to reduce incomplete local resection (R1,R2), local and systemic recurrences that are reported in up to 30% of patients who undergo surgery alone. Phase II studies of preop-CRT, with radiation doses in the 40-50 Gy range, and concurrent chemotherapy with 5-fluorouracil (5-FU)-cisplatin +/- paclitaxel, or cisplatin-paclitaxel, have reported subsequent RO resection rates of 80%-100%, with tumor sterilization achieved in 8%-49% of cases, and consequently improved local control. New chemotherapy regimens omitting 5-FU have reduced the incidence of severe esophagitis, unplanned hospitalization, with comparable efficacy. Among three randomised trials that compared preop-CRT to surgery alone, one shown a debatable survival advantage. Reducing local recurrence rates lead to a switch to more distant failures, and increasing the radiation dose beyond 45 Gy appears to be of little value. However, it should be remembered that preop-CRT has associated toxicity, and may increase postoperative mortality. Novel strategies, which include induction with chemotherapy followed by preop-CRT, and for radiation therapy, three dimensional conformation techniques, image fusioning, and improved definition of treatment volumes, are still considered experimental and should be tested in specialized centers.
authors.affiliation: Department of Radiation-Oncology, Besançon University Hospital, Boulevard Fleming, F-25030 Besançon Cedex, France. jean-francois.bosset@ufc-chu.univ-fcomte.fr
authors.forename: Jean-François
authors.initials: JF
authors.lastname: Bosset
authors.forename: F
authors.initials: F
authors.lastname: Lorchel
authors.forename: G
authors.initials: G
authors.lastname: Mantion
authors.forename: J
authors.initials: J
authors.lastname: Buffet
authors.forename: G
authors.initials: G
authors.lastname: Créhange
authors.forename: M
authors.initials: M
authors.lastname: Bosset
authors.forename: L
authors.initials: L
authors.lastname: Chaigneau
authors.forename: S
authors.initials: S
authors.lastname: Servagi
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000532:radiotherapy* / Q000601:surgery; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D004334:Drug Administration Schedule; D004938:Esophageal Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy* / Q000601:surgery; D016629:Esophagectomy; D004943:Esophagogastric Junction; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D017239:Paclitaxel / Q000008:administration & dosage; D011879:Radiotherapy Dosage; D016032:Randomized Controlled Trials as Topic
chemical_list: D017239:Paclitaxel; D002945:Cisplatin; D005472:Fluorouracil